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Apoptotic Effects of Genistein, Biochanin-A and Apigenin on 
LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition 
of Polo-like Kinase-1
Natural isoflavones and flavones are important dietary factors for prostate cancer 
prevention. We investigated the molecular mechanism of these compounds (genistein, 
biochanin-A and apigenin) in PC-3 (hormone-independent/p53 mutant type) and LNCaP 
(hormone-dependent/p53 wild type) prostate cancer cells. A cell growth rate and apoptotic 
activities were analyzed in different concentrations and exposure time to evaluate the 
antitumor activities of genistein, biochanin-A and apigenin. The real time PCR and 
Western blot analysis were performed to investigate whether the molecular mechanism of 
these compounds are involving the p21 and PLK-1 pathway. Apoptosis of prostate cancer 
cells was associated with p21 up-regulation and PLK-1 suppression. Exposure of genistein, 
biochanin-A and apigenin on LNCaP and PC-3 prostate cancer cells resulted in same 
pattern of cell cycle arrest and apoptosis. The inhibition effect for cell proliferation was 
slightly greater in LNCaP than PC-3 cells. In conclusion, flavonoids treatment induces up-
regulation of p21 expression, and p21 inhibits transcription of PLK-1, which promotes 
apoptosis of cancer cells. 
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INTRODUCTION
Prostate cancer is the second commonly occurring cancer in 
western countries as well as in Asian countries, and the inci-
dence rates are rapidly growing (1). The conventional approach-
es, such as radical prostatectomy, radiotherapy and hormonal 
therapy, have not been managed effectively for this cancer (2). 
  Among risk factors of prostate cancer, dietary habit is signifi-
cantly associated with reduced risks for prostate cancer (3). Iso-
flavones and flavones are recommended to reduce prostate can-
cer (4). The major isoflavones are genistein and biochanin-A. 
Genistein has anti-angiogenic effects and blocks the uncon-
trolled cancer cell growth, and the cytotoxic activity is based on 
tyrosine kinase inhibition and DNA topoisomerase II inhibition 
(5). The other important isoflavone is biochanin-A, a methoxyl-
ated isoflavone in red clover, which induces delay of the S phase 
into the G2/M phase progression (6), and is a powerful agonist 
of the human aryl-hydrocarbon (ArH) receptor (7). Plant flavone 
apigenin has the effect of cell growth inhibition, anti-inflamma-
tory, anticancer and free-radical scavenging properties (8). Api-
genin promotes cell cycle arrest and apoptosis, through induced 
G2/M phase cell cycle arrest by suppression of cyclin B (9, 10).
  Recent studies have shown that genistein, biochanin-A and 
apigenin inhibit the growth of prostate cancer cells via the pro-
motion of cell cycle arrest and apoptosis, but the exact cell-cycle 
mechanism remains unknown. Therefore, we focused on the cell 
division regulators. One of considering key regulator is polo-like 
kinases (PLKs), particularly, PLK-1 activity (11, 12). PLK-1 is a 
potent regulator for multiple cell cycle functions, including ac-
tivation of Cdc2, mitotic entry, bipolar spindle formation, centro-
some maturation, and cytokinesis (13). PLK-1 depletion results 
in induction of apoptosis, so the inhibition of PLK-1 activity is a 
promising approach for the anticancer therapy (14). The down-
regulation of PLK-1 expression occurs through a transcriptional Seo YJ, et al.  •  Apoptotic Mechanisms of Flavones and Isoflavones on Prostate Cancer
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repression mechanism (15), with this reason, p21 was investi-
gated as another key factor. p21 was reported as a negative PLK-1 
transcription regulator of cell cycle progression at G1 phase (16). 
  Until now, PLK-1 and p21 have been shown to have anti-can-
cer activity individually, but there is no report on the simultane-
ous detection in prostate cancer cells. Therefore, we investigat-
ed the apoptotic effects of genistein, biochanin-A and apigenin 
on the prostate cancer cell lines through p21 mediated PLK-1 
transcriptional regulation mechanism.
MATERIALS AND METHODS
Cell culture 
Two human prostate carcinoma cell lines differing in androgen 
association and p53 status were used in this study. LNCaP (wild-
type for p53, androgen-dependent) and PC-3 (mutant-type for 
p53, androgen-independent) were purchased from American 
Type Culture Collection (Rockville, MD, USA) and cultured in 
RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin. All of the cells were maintained 
at standard cell culture conditions (37°C, 5% CO2 in a humidi-
fied incubator).
Cell proliferation assay
Genistein, biochanin-A and apigenin (Sigma-Aldrich, St. Louis, 
MO, USA) were dissolved in dimethyl sulfoxide (DMSO) (final 
concentration 0.1% in medium). Cells (2 × 10
3) were plated in 
flat-bottomed 96-well plates and treated with 0, 10, 50 and 100 
μM of genistein and biochanin-A, and 0, 10, 20, 40, and 80 μM of 
apigenin, respectively. After incubation for 72 hr at 37°C, 20 μL 
of methyl thiazolyl tetrazolium (MTT) (Sigma-Aldrich) solution 
was added to each well and then the absorbance was measured 
at 490 nm using the VERSAmax microplate reader (Molecular 
Device, Sunnyvale, CA, USA).
Apoptosis assay
Cells (2 × 10
6) were cultured in 100 mm tissue culture dishes for 
24 hr, and treated with genistein (100 μM), biochanin-A (100 μM) 
and apigenin (40 μM). After 36 hr, the cells were washed with 
phosphate buffered saline (PBS), detached by treatment with 
Trypsin/EDTA, and then centrifuged at 1,000 g for 5 min. The 
collected cells were incubated in the dark with Annexin V-FITC 
and annexin binding buffer (1 × ) at 24°C for 15 min and then 
centrifuged at 1,000 g for 5 min. Annexin binding buffer (1 × ) 
and propidium iodide staining solution were added to the cells 
and analyzed using a FACS Calibur instrument (BD Bioscienc-
es, San Jose, CA, USA).
Quantitative real-time RT-PCR
RNA isolation was performed using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacture’s protocol. 
Reverted first strand cDNA Synthesis Kit (Fermentas Life Scienc-
es, Glen Burnie, MD, USA) was used for cDNA synthesis. Two 
micrograms of cDNA was used as a template for PCR reaction. 
The resulting cDNA samples were amplified by quantitative PCR 
in the presence of SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster, CA, USA). The following primers were used: GAPDH-
sense 5´-TGG GCT ACA CTG AGC ACC AG-3´ and -antisense 
5´-GGG TGT CGC TGT TGA AGT CA-3´, Plk1-sense 5´-ATA GAG 
CGT GAC GGC ACT GAG T-3´ and -antisense 5´-TGC TCG CTC 
ATG TAA TTG CG-3´, and p21-sense 5´-CAA AGG CCC GCT CTA 
CAT CTT-3´ and -antisense 5´-AGG AAC CTC TCA TTC AAC 
CGC-3´. The cycling conditions were as follows: initial denatur-
ation (10 min at 95°C), followed by 40 cycles of denaturation (15 
sec at 95°C), annealing (30 sec at 60°C) and elongation (30 sec at 
72°C) and a final extension (10 min at 72°C). The comparative 
Ct method was used to calculate the relative changes in gene 
expression in 7500 Fast Real-time PCR System (Applied Biosys-
tems). The relative changes of gene expression were calculated 
using the following formula: Fold change in gene expression, 
2
-ΔΔCt = 2-{ΔCt (treated samples)-ΔCt (untreated control)}, where ΔCt = Ct (detected 
genes)-Ct (GAPDH) and Ct represents threshold cycle number.
Western blot analysis 
Cells (2 × 10
6) were cultured in 100 mm tissue culture dishes for 
24 hrs, and were treated with genistein (100 μM), biochanin-A 
(60 μM) and apigenin (40 μM). After 48 hr, the cells were washed 
with PBS, detached by treatment with Trypsin/EDTA, and then 
centrifuged at 1,000 g for 5 min. The cells were lysed in RIPA lysis 
buffer (150 mM NaCl, 1% NP-40, 0.5% Doc, 0.1% SDS, 50 mM 
Tris [pH 8.0]). The lysed cells were centrifuged at 12,000 rpm for 
10 min. Protein determination was performed by using the BCA 
Protein Assay Reagent kit (Pierce, Rockford, IL, USA). Cell lysates 
(40 μg) were electrophoresed in 8% SDS polyacrylamide gels 
and transferred onto nitrocellulose membranes. After blotting 
in 5% non-fat dry milk in Tween 20 Tris-buffered saline (TTBS), 
the membranes were incubated in a blocking solution (25 mM 
tris [pH 7.5], 150 mM NaCl, 0.1% Tween 20, 5% skim milk) at 
room temperature for 1 hr and then probed with 1:200 dilution 
of mouse monoclonal antibody for p21 and PLK-1 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) at 4°C for 12 hr. The mem-
branes were then washed with TTBS and incubated with 1:1,000 
dilution of goat anti-mouse polyvalent IgG-HRP (Santa Cruz 
Biotechnology) at room temperature for 1 hr. The membranes 
were washed in TTBS, and bands were visualized on X-ray film 
using Immobilion Western Kit (Millipore, Bedford, MA, USA).
Data analysis 
Each experiment was repeated three times, and the results were 
analyzed by Student’s t test and one-way analysis of variance. A 
P value less than 0.05 was considered significant.Seo YJ, et al.  •  Apoptotic Mechanisms of Flavones and Isoflavones on Prostate Cancer
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RESULTS
Dose dependent inhibition of cell proliferation by 
genistein, biochanin-A and apigenin
LNCaP and PC-3 cells were treated with different doses of genis-
tein, biochanin-A or apigenin for 3 days, and cell viability was 
assessed by the MTT assay. Genistein, biochanin-A and apigenin 
induced decrease of cell viability of both cell lines in a dose-de-
pendent manner. Genistein and biochanin-A showed significant 
inhibition of cell proliferation at the dose of 50 and 100 μM. Api-
genin showed growth inhibition at 40 and 80 μM, significantly. 
More considerable reduction of cell viability occurred in LNCaP 
cells than in PC-3 cells treated with genistein and biochanin-A 
(Fig. 1). Isoflavones (genistein and biochanin-A) and flavone 
(apigenin) showed similar pattern for the reduction of cell via-
bility.
Induction of apoptosis by genistein, biochanin-A  
and apigenin 
Flow cytometric analysis of Annexin V-FITC showed that treat-
ment with genistein, biochanin-A and apigenin induced about 
3-fold increase (21.3%, 20.5% and 23.5%, respectively) in early 
apoptotic fraction (Q4) of LNCaP cells, compared to control group 
(7.4%). Late apoptotic fraction (Q2) of LNCaP cells showed about 
1.8-fold to 3.2-fold increase in apoptosis (7.9% for genistein, 6.9% 
for biochanin-A and 12.2% for apigenin) compared to control 
group (3.8%). In the analysis of combination of early and late 
apoptotic fraction, apoptosis was increased about 2.4- to 3.1-
fold (11.2% for control, 29.2% for genistein, 27.4% for biochanin-
A and 35.7% for apigenin) (P < 0.05) (Fig. 2A). 
  In PC-3 cells, treatment with genistein, biochanin-A and api-
genin induced about 2.5-fold to 4-fold increase in apoptosis 
(8.6%, 11.0% and 13.8%, respectively) in early apoptotic fraction, 
compared to control group (3.4%). The late apoptotic fraction 
showed about 1.6-fold to 8.7-fold increase in apoptosis (6.3%, 
14.9% and 2.8%, respectively) compared to control group (1.7%) 
(Fig. 2B). In the analysis of combination of early and late apop-
totic fraction, apoptosis was increased about 2.6- to 5-fold (5.1% 
for control, 14.9% for genistein, 25.9% for biochanin-A and 16.7% 
for apigenin) (P < 0.05) (Fig. 2B).
 
Up-regulation of p21 and inhibition of PLK-1 gene 
expression 
Inhibition of cell proliferation is through an arrest in cell-cycle 
and up-regulation of apoptosis. We investigated effect on cell 
cycle by evaluating the transcriptional expression of PLK-1 gene 
in prostate cancer cells. On LNCaP cell line, minimum 10 μM of 
genistein, 100 μM of biochanin-A and 40 μM of apigenin treat-
Fig. 1. Dose dependent inhibition of cell proliferation by genistein (GEN), biochanin-A (BIO) and apigenin (Api) on LNCaP and PC-3 prostate cancer cells. The data represent 
mean ± SD of six independent experiments. 
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ment showed p21 up-regulation, and 50 μM of genistein, 50 μM 
of biochanin-A and 40 μM of apigenin treatment showed PLK-1 
inhibition, significantly (P < 0.05).
  In the PC-3 cell line, minimum 100 μM of genistein, 50 μM of 
biochanin-A and 40 μM of apigenin treatment showed p21 up-
regulation, and 100 μM of genistein, 50 μM of biochanin-A and 
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Fig. 2. Induction of apoptosis by genistein, biochanin-A and apigenin on LNCaP and PC-3 prostate cancer cells.
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Fig. 3. Up-regulation of p21 and inhibition of PLK-1 gene expression by real-time PCR analysis treating genistein, biochanin-A and apigenin on LNCaP and PC-3 prostate can-
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40 μM of apigenin treatment showed PLK-1 inhibition signifi-
cantly, (P < 0.05) (Fig. 3).
p21 and PLK-1 protein regulation 
The effect of genistein, biochanin-A and apigenin on the pro-
tein expression of this signaling pathway was confirmed using 
western blot. The results indicated that genistein, biochanin-A 
and apigenin treatment for 48 hrs induced increase the expres-
sion of p21 and decrease of PLK-1 protein (Fig. 4).
 
DISCUSSION
Our experiment demonstrated that genistein, biochanin-A and 
apigenin affect inhibition of prostate cancer cell proliferation 
after induction of apoptosis through promoter element p21 for 
transcriptional inhibition of PLK-1. 
  The cell proliferation rate, flow cytometry, real-time PCR and 
western blot analysis showed that treatment of the flavonoids 
induced similar regulation mechanism for LNCaP and PC-3 cells. 
Genistein, biochanin-A and apigenin treatment caused a remark-
able decrease of PLK-1 expression levels. PLK-1 is a well-recog-
nized key regulator of the mitotic progression, notably, a close 
correlation observed between PLK-1 expression and carcinogen-
esis including prostate cancer (17). PLK-1 induced tumorigene-
sis is based on centrosome abnormality, particularly centrosome 
amplification defects. Centrosome duplication and maturation 
was regulated by PLK-1 at late S phase to prophase. PLK-1 over-
expression increases the centrosome size and number, which 
leads to multipolar spindles and unequal segregation of chro-
mosomes (18). While, PLK-1 inhibition results in inactivation of 
cyclin-dependent kinase 1 (Cdc2)/cyclin B 1-mediated mitotic 
arrest, which causes cell apoptosis (12).
  PLK-1 transcription level is controlled by regulator, located at 
promoter region. PLK-1 expression level is low at the G1→S tran-
sition, increases at the S phase, and maximum expression showed 
p21
PLK-1
β-actin
  Control  GEN  BIO  API   Control  GEN  BIO  API
LNCaP PC-3
Fig. 4. p21 mediated PLK-1 protein regulation by western blot analysis treating genistein, biochanin-A and apigenin on LNCaP and PC-3 prostate cancer cells. Genistein (GEN, 
100 µM), biochanin-A (BIO, 60 µM) and apigenin (API, 40 µM) were treated for 48 hr. Control cells (Ctrl) were treated with 0.1% DMSO.
at G2→M stage (12). One of a negative regulator of PLK-1 tran-
scription is p53, tumor suppressor gene, and the detailed connec-
tion of PLK-1 and p53 has been evaluated (19). However, other 
negative regulators for PLK-1 transcription are not studied inten-
sively yet. 
  Our experiment focused on a correlation of p21 expression 
and PLK-1 inhibition, because p21 controls PLK-1 transcription 
as a negative regulator in cancer cells (20). Using LNCaP and 
PC-3 cell lines, cell cycle analyses indicated that the genistein, 
biochanin-A and apigenin treatment showed an obvious delayed 
mitosis and this phenotype was associated with the elevation of 
p21. According to reports, elevation of p21 after PLK-1 inhibition 
might be a general phenomenon in normal and cancer cells (21, 
22). In normal cells, stabilization of p21 induces PLK-1 deple-
tion, which causes the elevation of p53. In cancer cells (p53-de-
fective), PLK-1 depletion reduced Mdm2 expression, a negative 
regulator of p21 protein stability (21). Thus, anti-cancer effects of 
genistein, biochanin-A and apigenin are associated with down-
regulation of PLK-1 and up-regulation of p21 mechanism.
  Our result is the first study for overexpression of p21 and sup-
pression of PLK-1 on prostate cancer cells through mechanism 
for p21 induced inhibition of PLK-1 transcription. Even though, 
there have been a few studies about the effect of flavonoids on 
the expression of PLK-1 and p21, all of them studied individual 
effect of p21 and PLK-1. Ismail et al. (23) reported that genistein 
induced PLK-1 down-regulation-mediated apoptosis and G2/M 
arrest on neuroblastoma cells. Reagan-Shaw and Ahmad (17) 
reported that blocking PLK-1 expression via siRNA induced apop-
tosis and G2/M arrest in human prostate cancer cells. Zhao et 
al. (24) showed that p21 was upregulated by genistein in both 
p53-expressing LNCaP and p53-null PC-3 cells. Apigenin expo-
sure increased p53 protein expression, which correlated with 
an increase in the levels of its transcriptional target p21 on pros-
tate cancer cells (25). 
  This study proved that one of anti-prostate cancer mechanisms Seo YJ, et al.  •  Apoptotic Mechanisms of Flavones and Isoflavones on Prostate Cancer
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by genistein, biochanin-A and apigenin through increase of p21 
pathway resulted in decreased PLK-1 expression as a conse-
quence of apoptotic cell death. Therefore, it is concluded that 
genistein, biochanin-A and apigenin treatment relates to the 
combined p21 and PLK-1 mechanism, which could be a poten-
tially attractive strategy in prostate cancer cell therapy.
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Genistein, biochanin-A and apigenin induce cell growth inhibition by increasing apoptosis in prostate cancer cells. These apoptotic 
mechanisms involved enhancement of p21 expression and inhibition of PLK-1 expression. Genistein, apigenin and biochanin- A 
may have antitumor activity and may be useful as an adjuvant to standard therapy for prostate tumors.